ALLERGY IMMUNOTHERAPY MARKET ANALYSIS

Allergy Immunotherapy Market Size and Trends

Global allergy immunotherapy market is estimated to be valued at USD 2,495.8 Mn in 2024 and is expected to reach USD 4,739.6 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.6% from 2024 to 2031.

Discover market dynamics shaping the industry: Request sample copy

Global allergy immunotherapy market is expected to witness significant growth over the forecast period due to  increasing prevalence of allergies such as allergy to pollen, dust, pet dander, insects bites and food allergies across the globe. Allergies have emerged as one of the major health issues affecting people of all age groups. Moreover, the development and approval of novel products such as sublingual and subcutaneous immunotherapy is expected to provide growth opportunities for market players. However, side effects associated with allergy immunotherapy and lack of awareness about available treatment options in developing countries can hamper the market growth during the forecast period.

Increasing Availability of Allergen Immunotherapy Solutions

The increasing availability of allergen immunotherapy solutions is one of the factors that is expected to drive the market growth during the forecast period. For instance, in June 2021, Stallergenes Greer, one of the global leaders in allergy immunotherapy, announced that the Alusta, subcutaneous allergen immunotherapy (SCIT) solution for different allergies involving rhinitis, conjunctivitis, rhino conjunctivitis, or asthma is now available in Spain and Italy.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Request sample copy

Basic and clinical research over the past decade has significantly expanded knowledge of how allergen immunotherapy works at the molecular level to provide long-lasting relief. Its complex effects on immune cells, cytokines and antibodies responsible for modifying the body's response to allergens are now increasingly well characterized. This growing scientific evidence base is enabling refinement and targeting of immunotherapy protocols. It is also translating to demonstrable real-world advantages over existing symptomatic therapies which treat only a fraction of patients successfully. Studies following thousands of patients for many years now prove immunotherapy can prevent new sensitizations from developing in addition to treating existing ones. Multiple long-term outcome studies also confirm that its benefits endure for 3-5 years after discontinuation of treatment. This disease-modifying impact sets it apart and raises expectations of altering the natural history of allergy in susceptible individuals

Key Takeaways from Analyst

Global allergy immunotherapy market growth is driven by rising prevalence of allergic diseases worldwide. Allergies have become increasingly common, owing to various environmental factors like pollution and changing lifestyle habits. This growing patient pool suffering from conditions like allergic rhinitis, asthma, and atopic dermatitis can boost demand for immunotherapy treatments over the forecast period.

North America dominates the market owing to high awareness levels and established healthcare infrastructure in the region. However, Asia Pacific is expected to witness the fastest growth rate in the near future due to growing healthcare expenditure and massive patient population suffering from allergies in the emerging countries of China and India.

Stringent regulations associated with product approval can hamper the market growth. High costs involved in clinical trials and regulatory approvals negatively impact shorter-term profit margins. However, longer regulatory exclusivity periods grant extended periods of revenue generation post-approval.

Market Challenges: High Costs Associated with Therapy

The high costs associated with allergy immunotherapy can hamper the global allergy immunotherapy market growth. Immunotherapy requires long-term commitment from patients as it involves years of regularly scheduled visits to the doctor's office for getting injections or pills. This prolonged treatment duration drastically increases the overall therapy costs. Moreover, each allergy immunotherapy prescription is custom-made for each individual patient based on their specific allergens. This customized production in a low volume adds to the per patient therapy costs.

Market Opportunities: Increasing Research and Development Activities by Key Market Players

Increasing research and development activities by market players is expected to offer lucrative growth opportunities over the forecast period. For instance, in August 2023, Inimmune Corporation (“Inimmune”), a clinical-stage company focused on the development of innovative immunotherapeutics, announced that the first subject has been dosed in Inimmune’s phase 1/1b First-in-Human clinical trial of INI-2004, Inimmune’s TLR4 agonist product candidate under development as a potential treatment of allergic rhinitis. The phase 1/1b trial is a randomized, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of INI-2004 in healthy volunteers and participants with allergic rhinitis (AR).

Discover high revenue pocket segments and roadmap to it: Request sample copy

Treatment Type segment is sub-segmented into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Tetrahydrocannabinol (THC) sub-segment is estimated to hold 52.8% of the market share in 2024, owing to its enduring efficacy and simplicity. SCIT involves administering graded doses of allergen extract under the skin, building tolerance slowly over time. This gradual, prolonged exposure allows the body to develop a tolerance and reduces the risk of severe allergic reactions that can occur with other treatments. Long-term studies show patients often experience symptom relief and reduce their medication usage for 3-5 years after completion of treatment. Its predictable response provides reassurance to both physicians and patients. Despite requiring weekly visits initially, compliance tends to be high because results materialize gradually over months of therapy versus sudden effects that could raise safety concerns. The straightforward delivery method of SCIT provides it an advantage. Administered in a doctor's office, it presents minimal burden on patients compared to daily at-home therapies. This simplicity boosts adherence and helps maximize treatment impact. It also allows for close monitoring by trained staff to promptly address any adverse reactions. Due to these risk-management advantages, SCIT remains the standard of care recommended in clinical practice guidelines for most common allergies like dust mites and pollen.

Insights, By Allergy Type: Demand for Effective Asthma Treatment Boosts Segment

Allergy Type segment is sub-segmented into allergic rhinitis, allergic asthma, food allergy, venom allergy, others. The allergic asthma sub-segment is estimated to hold 36.1% of the market share in 2024, owing to the rising prevalence of asthma globally. According to recent estimates by health organizations, over 300 million people suffer from asthma worldwide. The condition is characterized by inflammation of the airways and difficulty in breathing. Conventional treatment of acute asthma involves the use of short-acting beta-agonists to relax bronchial muscles. However, long-term control medications such as inhaled corticosteroids and leukotriene modifiers are essential to prevent recurrent symptoms. The asthma segment is driven by the need for more effective medicines that can better manage symptoms over prolonged use. Several drug makers are investing in research to develop novel biologic drugs targeting specific inflammatory pathways involved in asthma pathophysiology. Monoclonal antibody therapies that block immune system proteins like IgE and IL-5 have shown promising results in clinical trials. Such targeted drugs offer superior efficacy with less risk of side effects compared to existing options. Their approval and commercialization in major markets will provide a significant boost to the asthma segment in the coming years.

Insights, By Distribution Channel: Access and Awareness incline hospitals' lead in allergy immunotherapy distribution

Distribution Channel segment is sub-segmented into hospital pharmacies, retail pharmacies, online pharmacies. The hospital pharmacies sub-segment is estimated to hold 51.2% of the market share in 2024, due to their accessibility and promotion of services. As the traditional source for allergy treatments, hospitals provide convenient access for individuals seeking immunotherapy evaluation and ongoing treatment. Being located in most major medical areas, hospitals present minimal transportation hurdles for patients. Their extensive specialty clinics and on-site pharmacies allow for streamlined evaluations, prescriptions and dispensing within one facility. Patients appreciate the integrated 'one-stop-shop' for their care. Major hospitals also spearhead advancement in immunotherapy through dedicated research departments. Their position at the forefront of new protocol developments and clinical trials increases patients' confidence in outcomes. This reputation cements hospitals' leadership role and widens their reach, sustaining their position as the primary channel supplying allergy immunotherapy. With optimized logistics and continuous promotion, hospitals are optimally equipped to capture the highest market share.

Regional Insights

To learn more about this report, Request sample copy

North America remains the dominant region in the global allergy immunotherapy market and is estimated to hold 38.1% of the market share in 2024. The presence of leading pharmaceutical and biotechnology companies in the U.S. and Canada has propelled research and development activities in the region. Favorable reimbursement policies for immunotherapy procedures have ensured wider acceptance and adoption among patients and healthcare providers. Manufacturers in North America have developed a wide range of immunotherapy products for different allergens. The region is also home to several manufacturing facilities that cater to local as well as global demand. This enables companies to strengthen supply chain managements and address customer needs in a time-efficient manner.

Asia Pacific region has emerged as the fastest growing market for allergy immunotherapy. Rapid economic growth, rising healthcare standards, and growing incidences of allergies across nations like India and China are expected to drive the market growth. Local players are collaborating with global leaders to transfer technology and expertise. Governments are also introducing favorable regulations to boost indigenous manufacturing capabilities in the long term.

Market Report Scope

Allergy Immunotherapy Industry News

• On January 8, 2024, Inimmune Corporation (Inimmune) and Intrommune Therapeutics, Inc. (Intrommune), clinical-stage companies focused on the development of innovative immunotherapeutics, announced collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy
• In May 2021, Glenmark Pharmaceuticals Limited, a pharmaceutical company, launched Ryaltris-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India
• In December 2020, Novartis AG, a pharmaceutical company, announced that it had received an approval from U.S. Food and drug Administration for adults with nasal polyps
• In July 2020, Anergis SA, a company developing contiguous overlapping peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced that both companies had entered into a research collaboration. The study will be conducted at the Helmholtz Centre for Infection Research (HZI, Braunschweig, Germany) as part of TRANSVAC2, the European Network of Vaccine Research and Development funded under the European Union's Horizon 2020 Research and Innovation Program

*Definition: Allergy immunotherapy refers to treatments that help desensitize people to specific allergens like dust, pollen, animal dander, bee venom, or food, through controlled doses of the allergen, administered over months or years, to gradually reduce sensitivity and symptoms. It works by exposing the immune system to small but increasing amounts of an allergen to retrain it not to overreact.

Market Segmentation

• Treatment Type Insights (Revenue, USD Mn, 2019 - 2031)
  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)
    • 10-30 MeV
    • 30 -70 MeV
• Allergy Type Insights (Revenue, USD Mn, 2019 - 2031)
  • Allergic Rhinitis
  • Allergic Asthma
  • Food Allergy
  • Venom Allergy
  • Others
• Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Mn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Stallergenes Greer
  • ALK-Abello A/S
  • Allergy Therapeutics
  • Allergopharma
  • HAL Allergy Group
  • Aimmune Therapeutics
  • DBV Technologies
  • Leti Pharma
  • Jubilant HollisterStier
  • Merck KGaA
  • Biomay AG
  • Hollister Allergy
  • Aravax Pty Ltd
  • Allovate, LLC